Patients’ characteristics
| . | Patients with AML . | Healthy control group . |
|---|---|---|
| Demographic data | ||
| Median age (range), y∗ | 56 (17-90) | 30 (19-59) |
| Sex, %∗ | ||
| Female | 49.5 | 65.9 |
| Male | 50.5 | 34.1 |
| Population | German | German |
| Biobank, n | ||
| Collaborative Biobank | 505 | |
| Study Alliance Leukemia | 1265 | |
| Disease classification, %∗ | ||
| AML status | ||
| De novo AML | 88.9 | |
| Secondary AML | 10.4 | |
| Tertiary AML | 0.7 | |
| Disease status at the time of sample collection, % | ||
| Initial AML diagnosis | 100 | |
| European LeukemiaNet risk category, % | ||
| Favorable | 37.7 | |
| Intermediate | 57.4 | |
| Adverse | 4.7 | |
| Not applicable | 0.2 | |
| Eastern Cooperative Oncology Group, % | ||
| 0 | 20.2 | |
| 1 | 51.1 | |
| 2 | 16.8 | |
| 3 | 3.9 | |
| 4 | 1.4 | |
| Not applicable | 6.6 | |
| . | Patients with AML . | Healthy control group . |
|---|---|---|
| Demographic data | ||
| Median age (range), y∗ | 56 (17-90) | 30 (19-59) |
| Sex, %∗ | ||
| Female | 49.5 | 65.9 |
| Male | 50.5 | 34.1 |
| Population | German | German |
| Biobank, n | ||
| Collaborative Biobank | 505 | |
| Study Alliance Leukemia | 1265 | |
| Disease classification, %∗ | ||
| AML status | ||
| De novo AML | 88.9 | |
| Secondary AML | 10.4 | |
| Tertiary AML | 0.7 | |
| Disease status at the time of sample collection, % | ||
| Initial AML diagnosis | 100 | |
| European LeukemiaNet risk category, % | ||
| Favorable | 37.7 | |
| Intermediate | 57.4 | |
| Adverse | 4.7 | |
| Not applicable | 0.2 | |
| Eastern Cooperative Oncology Group, % | ||
| 0 | 20.2 | |
| 1 | 51.1 | |
| 2 | 16.8 | |
| 3 | 3.9 | |
| 4 | 1.4 | |
| Not applicable | 6.6 | |
Patient data only available for Study Alliance Leukemia biobank samples.